Overview

A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate if LiRIS 400 mg is safe and tolerable when administered to women with Interstitial Cystitis with Hunner's lesions, and to evaluate any change in the bladder or in IC symptoms, following LiRIS administration.

Phase:

Phase 1

Details

Lead Sponsor:

Allergan

Collaborator:

TARIS Biomedical, Inc.